Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
David Cameron, Vikash Kumar Sharma, Chandroday Biswas, Cathy Clarke, David Chandiwana & Purnima Pathak. (2023) Cost-effectiveness of ribociclib versus palbociclib in combination with an aromatase inhibitor as first-line treatment of postmenopausal women with HR+/HER2− advanced breast cancer: analysis based on final OS results of MONALEESA-2 and PALOMA-2. Journal of Medical Economics 26:1, pages 357-365.
Read now
Read now
Shaheenah Dawood, Joanne Wing-yan Chiu, Chiun-Sheng Huang, Shona Nag, Aumkhae Sookprasert, Yoon-Sim Yap & Mastura Md Yusof. (2020) Palbociclib and beyond for the treatment of HR + HER2- metastatic breast cancer: an Asian-Pacific perspective and practical management guide on the use of CDK4/6 inhibitors. Current Medical Research and Opinion 36:8, pages 1363-1373.
Read now
Read now
Anna Forsythe, David Chandiwana, Janina Barth, Marroon Thabane, Johan Baeck, Anastasiya Shor & Gabriel Tremblay. (2018) Is progression-free survival a more relevant endpoint than overall survival in first-line HR+/HER2− metastatic breast cancer?. Cancer Management and Research 10, pages 1015-1025.
Read now
Read now
Elena Galve-Calvo, Eva González-Haba, Joana Gostkorzewicz, Irene Martínez & Alejandro Pérez-Mitru. (2018) Cost-effectiveness analysis of ribociclib versus palbociclib in the first-line treatment of HR+/HER2− advanced or metastatic breast cancer in Spain. ClinicoEconomics and Outcomes Research 10, pages 773-790.
Read now
Read now
Nanxin Li, Yanni Hao, Andrew Kageleiry, Miranda Peeples, Anna Fang, Valerie Koo, Eric Q. Wu & Annie Guérin. (2016) Time on treatment of everolimus and chemotherapy among postmenopausal women with hormone-receptor-positive/human-epidermal-growth-factor-receptor-2-negative metastatic breast cancer: a retrospective claims study in the US. Current Medical Research and Opinion 32:2, pages 385-394.
Read now
Read now
Articles from other publishers (19)
Kevin BerriosAlexandra BurumEunae JeongLixian Zhong. (2022) Is adding ribociclib to fulvestrant cost-effective in treating postmenopausal women with HR+/HER2- advanced or metastatic breast cancer? A US payer perspective cost utility analysis. Journal of Managed Care & Specialty Pharmacy 28:11, pages 1282-1291.
Crossref
Crossref
Jennifer L. Caswell-Jin, Alison Callahan, Natasha Purington, Summer S. Han, Haruka Itakura, Esther M. John, Douglas W. Blayney, George W. SledgeJrJr, Nigam H. Shah & Allison W. Kurian. (2021) Treatment and Monitoring Variability in US Metastatic Breast Cancer Care. JCO Clinical Cancer Informatics:5, pages 600-614.
Crossref
Crossref
Eunae Jeong, Changjun Wang, Leslie Wilson & Lixian Zhong. (2021) Cost-Effectiveness of Adding Ribociclib to Endocrine Therapy for Patients With HR-Positive, HER2-Negative Advanced Breast Cancer Among Premenopausal or Perimenopausal Women. Frontiers in Oncology 11.
Crossref
Crossref
Yun Wu, Yiqun Han, Pei Yu, Quchang Ouyang, Min Yan, Xiaojia Wang, Xichun Hu, Zefei Jiang, Tao Huang, Zhongsheng Tong, Shusen Wang, Yongmei Yin, Hui Li, Runxiang Yang, Huawei Yang, Yuee Teng, Tao Sun, Li Cai, Hongyuan Li, Xi Chen, Jianjun He, Xinlan Liu, Shune Yang, Youlin Qiao, Jinhu Fan, Jiayu Wang & Binghe Xu. (2021) Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: A Nation-Wide Multicenter Epidemiological Study in China. Frontiers in Oncology 10.
Crossref
Crossref
Anna Maria Buehler, Gabriela Castilho, Pierre-Alexandre Dionne & Stephen Stefani. (2021)
Cost-effectiveness of ribociclib plus letrozole
versus
palbociclib plus letrozole or letrozole as monotherapy in first-line treatment of postmenopausal women with HR+/HER2− locally advanced or metastatic breast cancer: a Brazilian private payer perspective
. Therapeutic Advances in Medical Oncology 13, pages 175883592110005.
Crossref
Crossref
Anouk K.M. Claessens, Khava I.E. Ibragimova, Sandra M.E. Geurts, Monique E.M.M. Bos, Frans L.G. Erdkamp & Vivianne C.G. Tjan-Heijnen. (2020) The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice. Critical Reviews in Oncology/Hematology 153, pages 102988.
Crossref
Crossref
Olivia Le Saux, Audrey Lardy-Cleaud, Sophie Frank, Marc Debled, Paul H. Cottu, Barbara Pistilli, Laurence Vanlemmens, Marianne Leheurteur, Christelle Lévy, Lilian Laborde, Lionel Uwer, Veronique D'hondt, Delphine Berchery, Veronique Lorgis, Jean-Marc Ferrero, Genevieve Perrocheau, Coralie Courtinard, Marie Ange Mouret-Reynier, Michel Velten, Mathias Breton, Damien Parent, Sylvie Chabaud, Mathieu Robain & Thomas Bachelot. (2019) Assessment of the efficacy of successive endocrine therapies in hormone receptor–positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. European Journal of Cancer 118, pages 131-141.
Crossref
Crossref
Gaurav Suri, David Chandiwana, Adam Lee & Rohit Mistry. (2019) Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of Health Economics and Outcomes Research, pages 20-31.
Crossref
Crossref
Gaurav Suri, David Chandiwana, Adam Lee & Rohit Mistry. (2019) Cost-effectiveness Analysis of Ribociclib plus Letrozole versus Palbociclib plus Letrozole in the United Kingdom. Journal of Health Economics and Outcomes Research 6:2, pages 20-31.
Crossref
Crossref
Stacey A. Dacosta Byfield, Oluwakayode Adejoro, Ronda Copher, Debanjana Chatterjee, Prashant R. Joshi & Francis P. Worden. (2019) Real-World Treatment Patterns Among Patients Initiating Small Molecule Kinase Inhibitor Therapies for Thyroid Cancer in the United States. Advances in Therapy 36:4, pages 896-915.
Crossref
Crossref
Samantha K. Kurosky, Debanjali Mitra, Giovanni Zanotti & James A. Kaye. (2018) Treatment Patterns and Outcomes of Patients With Metastatic ER+/HER-2− Breast Cancer: A Multicountry Retrospective Medical Record Review. Clinical Breast Cancer 18:4, pages e529-e538.
Crossref
Crossref
Monika Parisi, Corey Pelletier, Dasha Cherepanov & Michael S Broder. (2018)
Outcomes research examining treatments, quality of life and costs in
HER2
-negative and triple-negative metastatic breast cancer: a systematic literature review
. Journal of Comparative Effectiveness Research 7:1, pages 67-83.
Crossref
Crossref
Giovanni Zanotti, Matthias Hunger, Julia J Perkins, Ruslan Horblyuk & Monique Martin. (2017) Treatment patterns and real world clinical outcomes in ER+/HER2- post-menopausal metastatic breast cancer patients in the United States. BMC Cancer 17:1.
Crossref
Crossref
Camille LaurentMarine BaronNadia AmaraCorinne HaiounMylène DandoitMarc MaynadiéMarie ParrensBeatrice VergierChristiane Copie-BergmanBettina FabianiAlexandra Traverse-GlehenNicole BrousseMarie-Christine CopinPatrick TasTony PetrellaMarie-Christine RousseletJosette BrièreFréderic CharlotteCatherine Chassagne-ClementThérèse RoussetLuc XerriAnne MoreauAntoine MartinDiane DamottePeggy DartiguesIsabelle SoubeyranMichel PeochPierre DechelotteJean-François MichielsAntoine de MascarelFrançoise BergerCéline BossardFlavie ArbionIsabelle Quintin-RouéJean-Michel PicquenotMartine PateyBlandine FabreHenri SevestreCécile Le NaouresMarie-Pierre Chenard-NeuClaire BastienSylvie ThiebaultLaurent MartinManuela DelageThomas FilleronGilles SallesThierry Jo MolinaGeorges DelsolPierre BroussetPhilippe Gaulard. (2017) Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. Journal of Clinical Oncology 35:18, pages 2008-2017.
Crossref
Crossref
Rita Caldeira & Mark Scazafave. (2016) Real-World Treatment Patterns for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer in Europe and the United States. Oncology and Therapy 4:2, pages 189-197.
Crossref
Crossref
Uwe Güth, Dorothy Jane Huang, Andreas Schötzau & Seraina Margaretha Schmid. (2016) Use of Palliative Endocrine Therapy in Patients with Hormone Receptor-Positive Distant Metastatic Breast Cancer: How Often, How Effective, How Long?. Oncology 90:1, pages 1-9.
Crossref
Crossref
Jipan Xie, Yanni Hao, Nanxin Li, Peggy L. Lin, Erika Ohashi, Valerie Koo & Eric Q. Wu. (2015) Clinical outcomes among HR+/HER2− metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Experimental Hematology & Oncology 4:1.
Crossref
Crossref
Adam M. Brufsky. (2015) Delaying Chemotherapy in the Treatment of Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer. Clinical Medicine Insights: Oncology 9, pages CMO.S31586.
Crossref
Crossref
Nanxin Li, Yanni Hao, Jipan Xie, Peggy L. Lin, Valerie Koo, Erika Ohashi & Eric Q. Wu. (2015) Everolimus-Based Therapy versus Chemotherapy among Patients with HR+/HER2− Metastatic Breast Cancer: Comparative Effectiveness from a Chart Review Study. International Journal of Breast Cancer 2015, pages 1-9.
Crossref
Crossref